多参数磁共振成像评估不同乳腺癌亚型新辅助全身治疗后的反应:不同病理完全缓解定义的比较
回顾性纳入2015年1月至2017年6月接受新辅助全身治疗的81例女性82个乳腺癌病灶,比较以ypT0与ypT0/is两种病理完全缓解定义时多参数MRI评估病理反应的效能。MRI晚期强化与病理反应显著相关(p<0.001),联合晚期强化、ADC比值和肿瘤亚型的多变量模型在ypT0和ypT0/is定义下准确率分别为86%和84%。作者认为ypT0/is似乎是更可取的病理完全缓解定义。
要点
- MRI晚期强化与病理反应显著相关(p<0.001),不受ypT0或ypT0/is定义影响。
- 联合晚期强化、ADC比值和免疫组化亚型的多变量模型评估病理反应准确率在ypT0下为86%、ypT0/is下为84%。
- HER2阳性亚型反应最佳(ypT0下53%、ypT0/is下48%),三阴性和HER2阳性肿瘤阴性预测值最高,luminal B-like亚型阳性预测值最高。
核心结论
- MRI晚期强化和ADC比值联合乳腺癌免疫组化亚型可高准确率识别新辅助全身治疗后的病理反应,三阴性和HER2阳性肿瘤阴性预测值最高,luminal B-like亚型阳性预测值最高,不受ypT0或ypT0/is定义影响。
- 鉴于残留导管原位癌不影响生存率,作者认为ypT0/is似乎是更可取的病理完全缓解定义。
研究设计与样本
- 机构审查委员会批准的回顾性研究,豁免知情同意。
- 2015年1月至2017年6月纳入81例女性82个接受新辅助全身治疗的乳腺癌病灶。
- 免疫组化亚型分布:HER2阳性18个病灶(22%)、三阴性12个(15%)、luminal B-like 42个(51%)、luminal B-like/HER2阳性10个(12%)。
- 新辅助全身治疗前后行乳腺MR成像,以ypT0和ypT0/is两种病理完全缓解定义分别进行对比分析,评估单变量和多变量模型预测病理反应的效能。
诊断标准与关键数值
- ypT0定义(无任何残留浸润癌或导管原位癌)下病理完全缓解率为23%(19/82),ypT0/is定义(无浸润肿瘤细胞)下为33%(27/82)。
- ypT0定义下HER2阳性亚型反应率为53%,ypT0/is定义下为48%。
- 晚期强化与病理反应显著相关(p<0.001),无论采用哪种病理完全缓解定义。
- ypT0定义下,病理完全缓解组平均ADC比值显著高于非病理完全缓解组(p=0.021);ypT0/is定义下未见显著关系。
- 包含MR晚期强化、ADC比值和肿瘤亚型的多变量模型在ypT0和ypT0/is定义下识别病理反应的准确率分别为86%和84%。
临床应用与阅片要点
- 阅片时可关注新辅助全身治疗后的MRI晚期强化和ADC比值,并结合免疫组化亚型综合评估病理反应。
- 三阴性和HER2阳性肿瘤中该模型阴性预测值最高,luminal B-like亚型中阳性预测值最高。
- 作者认为ypT0/is似乎是更可取的病理完全缓解定义,因残留导管原位癌不影响生存率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To validate the performance of multiparametric magnetic resonance (MR) imaging to assess pathologic response to neoadjuvant systemic therapy (NST) in various breast cancer subtypes considering two definitions of pCR: absence of any residual invasive cancer or DCIS (ypT0) and absence of invasive tumour cells (ypT0/is).
METHODS: Institutional review board-approved retrospective study, with waiver of the need to obtain informed consent. From January 2015 to June 2017, 81 women with 82 breast cancers undergoing NST were included. Eighteen lesions (22%) were immunohistochemically HER2-positive, 12 (15%) triple negative (TN), 42 (51%) luminal B-like and 10 (12%) luminal B-like/HER2-positive. Breast MR imaging was performed before and after NST. A comparative analysis considering pCR as ypT0 and ypT0/is was carried out. Performance of univariate and multivariate models to potentially predict pathologic response were evaluated.
RESULTS: ypT0 was attained in 23% (19/82) of cases and ypT0/is in 33% (27/82) of cases. In both scenarios, HER2-positive subtype achieved the best response, 53% and 48%, respectively. A significant relationship was found between late enhancement and pathologic response (p < 0.001) regardless of pCR definition. In the ypT0 scenario, mean ADC ratio in the pCR subgroup was significantly higher than that in the non-pCR subgroup (p = 0.021) but no significant relationship was noted in ypT0/is. A multivariate model including MR late enhancement, ADC ratio and tumor subtype identified pathologic response with 86% and 84% accuracy when ypT0 and ypT0/is were considered, respectively.
CONCLUSION: MR imaging late enhancement and ADC ratio along with breast cancer IHC subtype identify pathologic response following NST with high accuracy, achieving the highest NPV in TN and HER2-positive tumors and the highest PPV in luminal B-like subtypes, regardless of the definition of pCR as ypT0 or ypT0/is. In light of these findings and given that residual DCIS does not have an impact on survival rates, ypT0/is seems to be the preferable definition of pCR.
引用
- Santamaría G, Bargalló X, Ganau S, et al. Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. Eur J Radiol. 2019. PMID: 31307638. doi:10.1016/j.ejrad.2019.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。